On June 4, 2023 Harbour BioMed (HKEX: 02142) reported that the first patient has been dosed in its ongoing phase I trial of the first-in-class anti-B7H7 (HHLA2) antibody HBM1020 (NCT05824663/Study 1020.1) in the United States (Press release, Harbour BioMed, JUN 4, 2023, View Source [SID1234632431]). This study is evaluating the safety, tolerability, pharmacokinetics, and anti-tumor activity of HBM1020 in patients with advanced solid tumors.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

HBM1020, generated from Harbour Mice H2L2 transgenic mice platform, is the first therapeutic monoclonal antibody against B7H7/HHLA2 entering clinical development globally.

"We are delighted to announce the dosing of the first patient with our first-in-class B7H7/HHLA2 antibody HBM1020," said Dr. Jingsong Wang, Founder, Chairman and Chief Executive Officer of Harbour BioMed. "This milestone is a significant accomplishment for our team and represents a major step forward in our mission to transform patient care. We are excited about the potential of the B7H7/HHLA2 antibody to make a meaningful difference in the lives of patients suffering from advanced malignancies and we remain dedicated to advancing its clinical development globally."

About HBM1020
HBM1020 is a first-in-class fully human monoclonal antibody generated from Harbour Mice H2L2 transgenic mice platform, targeting B7H7/HHLA2.

B7H7, also known as HHLA2, is a novel immune modulatory molecule belonging to the B7 family. The B7 family is of central importance in regulating the T-cell response, making these pathways very attractive in cancer immunotherapy. Most of the validated targets in immune-oncology so far are related to B7 family, including PD-(L)1, and CTLA-4. The therapies against B7 family targets have already shifted the paradigm for cancer therapy with outstanding clinical benefits. As a newly discovered member of the B7 family, B7H7 expression is found non-overlapping with PD-L1 expression in multiple tumor types, which indicates an alternative immune evasion pathway besides PD-(L)1. In PD-L1 negative/ refractory patients, B7H7 potentially plays a critical role for tumor cells to escape immune surveillance. HBM1020 can enhance anti-tumor immunity by blocking the novel immune checkpoint target. Preclinical data demonstrated its immune activation and anti-tumor functional activities.

With its innovative biology mechanisms, HBM1020 presents a novel anti-tumor therapeutics complementary to PD-(L)1 therapeutics to patients, especially for PD-L1 negative/refractory patients.